Arena sheds ties to weight drug Belviq, completing a makeover
From now on, you can scratch any lingering rep Arena Pharmaceuticals $ARNA had as an obesity-focused biotech. Four-and-a-half years after the FDA approved its weight drug Belviq for marketing, and long after visions of blockbuster sales vanished like a mirage, the biotech has sold off rights to the drug to its partner Eisai and backed away from any remaining financial commitment for further trial work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.